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We have identified both high-affinity (KD = 36 + 3 nM) and low-affinity (KD = 2.1 _ 0.8/tM) prostacyclin (PGI2)-receptor 
sites on human erythroleukemia (HEL) cells using the radiolabelled prostacyclin analogue, [aH]iloprost. The addition 
of the phorbol ester, TPA, to the culture medium caused a 5-10-fold increase in the number of both the low- and the 
high-affinity sites, without any change in their affinity constants. Iloprost stimulated HEL cell membrane adenylate 
cyclase activity 5-fold. This stimulation was potentiated in the presence of GTP, indicating a conventional PGI 2 receptor- 
Gcadenylate cyclase system. HEL cells represent a source of prostacyclin receptor mRNA which may be of value in ex- 
pression cloning of this receptor. 
Prostacyclin receptor; Phorbol ester; Adenylate cyclase 
1. INTRODUCTION 
Prostacyclin (PGI2) is a potent platelet inhibitor 
and vasodilator. PGI2 receptor sites have been 
identified in several tissues, including platelets 
[1,2], vascular smooth muscle [3] and the NCB-20 
cell line [4]. Both the platelet and vascular effects 
of PGI2 appear to be mediated, via a G-protein, by 
the adenylate cyclase nzyme. 
Studies of the expression of platelet proteins 
have been difficult to perform due to the low 
capacity of the platelet for protein biosynthesis. 
Megakaryocytes, the platelet precursor cells, syn- 
thesize platelet proteins [5], but they are difficult to 
isolate in significant quantities. However, a human 
erythroleukemia (HEL) cell line has been establish- 
ed which expresses several megakaryocytic markers 
of differentiation. It has also been observed that 
the phorbol ester 12-O-tetradecanoyl-phorbol-13- 
acetate (TPA) induces the expression of various 
megakaryocyte/platelet markers in HEL cells [6]. 
In this study, we have examined the expression 
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of PGI2 receptors and the coupling of the receptor 
to adenylate cyclase in HEL cells. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Human erythroleukemia cells (HEL) were purchased from 
the American Type Culture Collection (ATCC) and cultured in 
suspension i RPMI 1640 medium supplemented with 10% fetal 
calf serum and antibiotics. TPA was dissolved in dimethyl sulf- 
oxide (DMSO) and added to the culture medium at a final con- 
centration of 160 nM for a period of 3 days. 
2.2. [3H]lloprost binding 
The HEL cell suspension (5x 106 cells/ml) was incubated for 
30min at room temperature with 100nM [~H]iloprost 
(14.7 Ci/mmol) and 0-10/,M unlabelled iloprost in 50 mM 
Tris. HC1 buffer, pH 7.4, containing 5 mM MgCI2, in a final 
volume of 0.2 ml. The reaction was terminated by rapid filtra- 
tion and washing on Whatman GF/C glass fibre filters. After 
addition of 10 ml of scintillation fluid, the filters were assayed 
for radioactivity. 
Binding analyses were performed by computerized non-linear 
curve fitting using the LIGAND program, as described by Mun- 
son and Robard [7]. 
2.3. Adenylate cyclase assays 
HEL cell membranes were prepared following lysis of the ceils 
in hypotonic PBS containing 0.1 mM PMSF. The cells were 
then dounce homogenized and the nuclei and undisrupted cells 
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removed by centrifugation at800 × g for 10 min. The superna- 
tant was centrifuged at 100000 x g for 1 h, and the resultant 
membrane pellet was resuspended in 50 mM Tris- HCI, pH 7.4, 
containing 5 mM MgCI2 and 1 mM EDTA and stored at - 70°C 
until use. 
Adenylate cyclase activity was measured by the method of 
Salomon et al. [8]. ~2p-labelled cyclic AMP was separated by se- 
quential chromatography on Dowex and alumina columns. 
Results are expressed as means _+ SE. 
3. RESULTS 
Binding of [3H]iloprost o HEL cells yielded a 
curvilinear Scatchard plot, indicating that, there 
were two PGI2-binding sites present (fig.l). The 
high-affinity-binding site had a KD = 36 _+ 3 nM 
and Bmax = 54 _ 10 fmol/106 cells. There were ap- 
proximately five times as many low-affinity- 
binding sites, with KD = 2.1 _+ 0.8/~M and Bmax = 
293 _+ 56 fmol/106 cells (n = 8). 
We investigated the functional coupling of these 
PGI2 receptors to the adenylate cyclase nzyme in 
HEL cell membranes. Iloprost (100 nM) maximal- 
ly stimulated adenylate cyclase activity 5-fold. The 
ECso for iloprost stimulation was 2 nM (fig.2). 
This is consistent with adenylate cyclase stimula- 
tion being mediated through the high-affinity 
iloprost-binding site. 
The stimulation of adenylate cyclase by iloprost 
was potentiated in the presence of GTP, indicating 
that the stimulation is mediated by Gs, the 
adenylate cyclase stimulatory G-protein. The non- 
hydrolysable GTP analogs, Gpp(NH)p and 
GTPTS both stimulated adenylate cyclase activity, 
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Fig.1. Scatchard plot of [3H]iloprost binding to HEL cells (a 
representative experiment). 
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Fig.2. Stimulation of HEL cell membrane adenylate cyclase ac- 
tivity by iloprost (n = 4). 
as did sodium fluoride, which also directly 
stimulates Gs (table 1). 
We investigated the effect of TPA on the expres- 
sion of the PGI2 receptor in the HEL cells. In cells 
treated with 160 nM TPA, concomitant with the 
well characterized change in morphology of the 
cells, there was a significant (p< 0.01) increase in 
the density of both the high- and the low-affinity- 
binding sites (table 2). There was no change in the 
affinity of iloprost for these sites. 
4. DISCUSSION 
The present study demonstrates the presence of 
PGI2 receptors in the HEL cell line. We have iden- 
tified a high- and a low-affinity site for [3H]il- 
oprost. Two affinity states of the PGI2 receptor 
have been identified in several tissues, e.g. platelets 
Table 1 
Stimulation of HEL cell membrane adenylate cyclase activity 
(n = 4) 
Stimulant Specific activity 
(pmol/mg per min) 
Basal 4.0 :t: 1.7 
GTP (10/zM) 6.0 +_ 1.2 
Iloprost (1/~M) 21.3 _+ 1.4 
Iloprost (1/zM) + GTP (10/zM) 35.1 _+ 3.7 
Gpp(NH)p (10/~M) 57.0 _+ 6.4 
GTPyS (1/~M) 75.6 _+ 4.0 
NaF (10 mM) 56.0 _+ 3.0 
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Table 2 
Effect of the phorbol ester, TPA, on PGI2 receptor number in 
HEL cells (n = 7) 
Bmax (receptor sites/cell) 
High-affinity s i te  Low-affinity site 
Control 0.4 ± 0.05 x l0 s 1.7 _+ 0.3 × 105 
TPA-treated 2.1 + 0.2 x 10 s 14.0 _+ 4.0 × 105 
[2], lung homogenate [9] and membranes from cor- 
onary arteries [3]. The high-affinity state of  the 
receptor in HEL  cells is the site which is coupled to 
stimulation of  the adenylate cyclase enzyme by il- 
oprost,  as has previously been reported in plate!et 
membranes [1,2]. This stimulation is mediated by a 
G-protein, probably Gs, as shown by the potentia- 
t ion o f  i loprost stimulation of  adenylate cyclase in 
the presence of  10/~M GTP.  Stable GTP analogs, 
Gpp(NH)p and GTPTS also stimulated cyclase ac- 
tivity in these membranes, even in the absence of  il- 
oprost, suggesting a strong PGI2 receptor-Gs 
coupling in these cells [10]. 
It has previously been reported that treatment of  
HEL  cells with phorbol  esters induces a dramatic 
macrophage-l ike shift in the phenotype of  these 
ceils [11]. This shift has been shown to be 
associated with the increased expression of  several 
platelet proteins, for example glycoproteins I Ib 
and I l la,  platelet factor 4 [6] and more recently the 
thromboxane A2 receptor [12]. We investigated the 
regulation of  expression of  the PGI2 receptor by 
the phorbol  ester, TPA.  The number of  both high- 
and low-affinity sites increased 5-10-fold following 
TPA treatment. The affinity of  these sites for [3H]- 
i loprost did not change, however, indicating that 
the number but not the nature of  the sites has been 
altered by TPA.  
The PGI2 receptor identified on HEL  cells is 
similar to that present in platelets. The treatment of  
these cells with TPA represents a useful means of  
amplifying the expression of  this receptor. These 
studies identify a source of  mRNA for expression 
cloning of  the PGI2 receptor. 
Acknowledgements: Supported by grants (HL30400) from the 
National Institute of Health and from Daiichi Seiyaku. R.M. is 
the recipient of a fellowship from the American Heart Associa- 
tion (Tennessee Affiliate). G.A.F. is an established investigator 
of the American Heart Association and is the William Stokes 
Professor of Experimental Therapeutics. 
REFERENCES 
[1] Siegl, A.M., Smith, J.B., Silver, M.J., Nicolaou, K.C. and 
Ahem, D. (1979) J. Clin. Invest. 63,215-220. 
[2] Sheperd, G.L., Lewis, P.J., Blair, I.A., DeMey, C. and 
MacDermot, J. (1983) Br. J. Pharmacol. 15, 77-81. 
[3] Town, M.-H., Schillinger, E., Speckenbach, A. and Prior, 
G. (1982) Prostaglandins 24, 61-71. 
[4] Blair, I.A. and MacDermot, J. (1981) Br. J. Pharmacol. 
72, 435-441. 
[5] Ryo, R., Nakeff, A., Huang, S.S., Ginsberg, M. and 
Deuel, T.F. (1983) J. Cell. Biol. 96, 515-520. 
[6] Tabilio, A., Rosa, J.-P., Testa, U., Kieffer, N., Nurden, 
A.T., Del Canzio, M.C., Breton-Gorius, J. and 
Valnchenker, W. (1984) EMBO J. 3, 453-459. 
[7] Munson, P.J. and Robard, D. (1980) Anal. Biochem. 107, 
220-239. 
[8] Salomon, Y., Londos, C. and Rodbell, M. (1974) Anal. 
Biochem. 58, 541-548. 
[9] MacDermot, J., Barnes, P.J., Waddell, K.A., Dollery, 
C.T. and Blair, I.A. (1981) Eur. J. Pharmacol. 75, 
127-130. 
[10] Murray, R. and Keenan, A.K. (1989) Cell. Signal. 1, 
173-179. 
[11] Papayannopoulou, T., Nakamoto, B., Yokochi, T., 
Chait, A. and Kannagi, R. (1983) Blood 62, 832-845. 
[12] Nakajima, M., Yamamoto, M., Ushikubi, F., Okuma, 
M., Fugiwara, M. and Narumiya, S. (1989) Biochem. Bio- 
phys. Res. Commun. 58, 958-965. 
174 
